Synonym
Losartan; DUP 89; DUP-89; DUP89;
IUPAC/Chemical Name
(1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol
InChi Key
PSIFNNKUMBGKDQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
SMILES Code
OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Biological target:
Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
In vitro activity:
Losartan improved TGF-β1-mediated inhibition of ETI-corrected F508del-CFTR function and reduced TNFA and COX2 mRNA and TNF-α protein expression.
Reference: J Clin Invest. 2022 Jun 1;132(11):e155241. https://pubmed.ncbi.nlm.nih.gov/35446787/
In vivo activity:
Hence, this study was designed to gain insight on whether losartan, a selective angiotensin II type 1 receptor (AT1R) antagonist, has therapeutic benefit to reverse IFP/synovial fibrosis and secondarily to attenuate pain behavior. Administration of once-daily losartan for 28-days dose-dependently attenuated the development of static weight bearing. Chronic treatment of MIA-rats with losartan had an anti-fibrotic effect and it attenuated pain behavior in this animal model.
Reference: Biomed Pharmacother. 2023 Feb;158:114121. https://pubmed.ncbi.nlm.nih.gov/36516695/
|
Solvent |
mg/mL |
mM |
| Solubility |
| Ethanol |
82.0 |
193.89 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
422.92
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Kim MD, Bengtson CD, Yoshida M, Niloy AJ, Dennis JS, Baumlin N, Salathe M. Losartan ameliorates TGF-β1-induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies. J Clin Invest. 2022 Jun 1;132(11):e155241. doi: 10.1172/JCI155241. PMID: 35446787; PMCID: PMC9151698.
2. Song Y, Li H, Ma S, Zhu M, Lu WJ, Lan F, Cui M. Losartan protects human stem cell-derived cardiomyocytes from angiotensin II-induced alcoholic cardiotoxicity. Cell Death Discov. 2022 Mar 28;8(1):134. doi: 10.1038/s41420-022-00945-2. PMID: 35347130; PMCID: PMC8960777.
3. Sriwatananukulkit O, Desclaux S, Tawonsawatruk T, Srikuea R, Himakhun W, Likitnukul S, Hemstapat R. Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain. Biomed Pharmacother. 2023 Feb;158:114121. doi: 10.1016/j.biopha.2022.114121. Epub 2022 Dec 12. PMID: 36516695.
4. Dos Santos LLM, Alves MG, Chies AB, Spadella MA. Losartan Attenuates Radiation-Induced Damage on Testes and Accelerates Tubular Regeneration. Front Reprod Health. 2022 Jul 14;4:904804. doi: 10.3389/frph.2022.904804. PMID: 36303628; PMCID: PMC9580693.
In vitro protocol:
1. Kim MD, Bengtson CD, Yoshida M, Niloy AJ, Dennis JS, Baumlin N, Salathe M. Losartan ameliorates TGF-β1-induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies. J Clin Invest. 2022 Jun 1;132(11):e155241. doi: 10.1172/JCI155241. PMID: 35446787; PMCID: PMC9151698.
2. Song Y, Li H, Ma S, Zhu M, Lu WJ, Lan F, Cui M. Losartan protects human stem cell-derived cardiomyocytes from angiotensin II-induced alcoholic cardiotoxicity. Cell Death Discov. 2022 Mar 28;8(1):134. doi: 10.1038/s41420-022-00945-2. PMID: 35347130; PMCID: PMC8960777.
In vivo protocol:
1. Sriwatananukulkit O, Desclaux S, Tawonsawatruk T, Srikuea R, Himakhun W, Likitnukul S, Hemstapat R. Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain. Biomed Pharmacother. 2023 Feb;158:114121. doi: 10.1016/j.biopha.2022.114121. Epub 2022 Dec 12. PMID: 36516695.
2. Dos Santos LLM, Alves MG, Chies AB, Spadella MA. Losartan Attenuates Radiation-Induced Damage on Testes and Accelerates Tubular Regeneration. Front Reprod Health. 2022 Jul 14;4:904804. doi: 10.3389/frph.2022.904804. PMID: 36303628; PMCID: PMC9580693.
1: Prasanna N, Subbarao CV, Gutmann JL. The efficacy of pre-operative oral medication of lornoxicam and diclofenac potassium on the success of inferior alveolar nerve block in patients with irreversible pulpitis: a double-blind, randomised controlled clinical trial. Int Endod J. 2011 Apr;44(4):330-6. PubMed PMID: 21692235.
2: Shah DA, Patel NJ, Baldania SL, Chhalotiya UK, Bhatt KK. Stability indicating LC-method for estimation of paracetamol and lornoxicam in combined dosage form. Sci Pharm. 2011 Mar;79(1):113-22. doi: 10.3797/scipharm.1012-03. Epub 2011 Jan 20. PubMed PMID: 21617776; PubMed Central PMCID: PMC3097499.
3: Yakhno N, Guekht A, Skoromets A, Spirin N, Strachunskaya E, Ternavsky A, Olsen KJ, Moller PL. Analgesic efficacy and safety of lornoxicam quick-release formulation compared with diclofenac potassium: randomised, double-blind trial in acute low back pain. Clin Drug Investig. 2006;26(5):267-77. PubMed PMID: 17163260.
4: Li C, Yang X, Ma X, Li L, Shi Z. Preoperative oral nonsteroidal anti-inflammatory drugs for the success of the inferior alveolar nerve block in irreversible pulpitis treatment: a systematic review and meta-analysis based on randomized controlled trials. Quintessence Int. 2012 Mar;43(3):209-19. Review. PubMed PMID: 22299121.
5: Hitoglou-Makedou A, Lawson M, Turner P, Ferber HP. Comparison of chlortenoxicam and indomethacin on frusemide-induced diuresis. Postgrad Med J. 1989 Nov;65(769):821-3. PubMed PMID: 2694142; PubMed Central PMCID: PMC2429206.
